Skip to Content
Merck
All Photos(1)

Documents

PHR1289

Supelco

Enalapril Maleate

Pharmaceutical Secondary Standard; Certified Reference Material

Synonym(s):

Enalapril maleate salt, (S)-N-[1-(Ethoxycarbonyl)-3-phenylpropyl]-Ala-Pro maleate salt

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C20H28N2O5 · C4H4O4
CAS Number:
Molecular Weight:
492.52
EC Number:
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material
pharmaceutical secondary standard

Quality Level

Agency

traceable to BP 741
traceable to Ph. Eur. E0109000
traceable to USP 1235300

API family

enalapril

CofA

current certificate can be downloaded

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-30°C

SMILES string

C[C@@H](C(N1[C@H](C(O)=O)CCC1)=O)N[C@H](CC(OCC)=O)CCC2=CC=CC=C2.O=C(OO)/C=C\C(O)=O

InChI

1S/C21H30N2O5.C4H4O5/c1-3-28-19(24)14-17(12-11-16-8-5-4-6-9-16)22-15(2)20(25)23-13-7-10-18(23)21(26)27;5-3(6)1-2-4(7)9-8/h4-6,8-9,15,17-18,22H,3,7,10-14H2,1-2H3,(H,26,27);1-2,8H,(H,5,6)/b;2-1-/t15-,17-,18-;/m0./s1

InChI key

UQKQUZOIQFOJOI-KJHLASMFSA-N

Looking for similar products? Visit Product Comparison Guide

General description

Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards. Enalapril Maleate is a drug, which is widely used as an antihypertensive and a vasodilator in congestive heart failure. It is a derivative of 2 amino acids such as L-alanine and L-proline.

Application

Enalapril Maleate may be used as a pharmaceutical reference standard for the quantification of the analyte in pharmaceutical formulations using derivative UV spectrophotometry and chromatography techniques.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

Biochem/physiol Actions

A long-acting angiotensin-converting enzyme inhibitor.

Analysis Note

These secondary standards offer multi-traceability to the USP, EP (PhEur) and BP primary standards, where they are available.

Other Notes

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

Footnote

To see an example of a Certificate of Analysis for this material enter LRAC3898 in the slot below. This is an example certificate only and may not be the lot that you receive.

Pictograms

Health hazard

Signal Word

Warning

Hazard Statements

Hazard Classifications

Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 2


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Determination of hydrochlorothiazide and enalapril maleate in tablet formulations by reversed-phase HPLC
Al-Momani GI
Turkish Journal of Chemistry, 25(1), 49-54 (2001)
Eran Leshem-Rubinow et al.
Mayo Clinic proceedings, 87(12), 1189-1195 (2012-11-13)
To investigate whether treatment initiated with an angiotensin-converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB) for patients with ischemic heart disease, hypertension, or diabetes causes a reduction in hemoglobin (Hb) levels. This was a retrospective cohort analysis
Justin Brewer et al.
Hypertension (Dallas, Tex. : 1979), 62(5), 886-892 (2013-09-18)
Hypertension during preeclampsia is associated with increased maternal vascular sensitivity to angiotensin II (ANGII). This study was designed to determine mechanisms whereby agonistic autoantibodies to the ANGII type I receptor (AT1-AA) enhance blood pressure (mean arterial pressure [MAP]) and renal
Fernando Arturo Reyes-Marín et al.
Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion, 64(4), 315-321 (2012-12-12)
Residual renal function (RRF) is an important determinant of mortality and morbidity in patients receiving peritoneal dialysis (PD). Recent studies have shown a positive effect of angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs) on RRF in
Donald E Stull et al.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 16(1), 164-176 (2013-01-23)
To present a step-by-step example of the examination of heterogeneity within clinical trial data by using a growth mixture modeling (GMM) approach. Secondary data from a longitudinal double-blind clinical drug study were used. Patients received enalapril or placebo and were

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service